Transcriptomic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI

Approximately 10% of EGFR- or ALK-driven lung adenocarcinomas treated with tyrosine kinase inhibitors (TKIs) transform into neuroendocrine carcinoma. These transformed tumors retain the original driver mutations of the adenocarcinoma, consistent with a phenotypic transformation instead of new primary tumor development. The underlying mechanisms involved in TKI-induced neuroendocrine transformation and the impact of transcriptomic and immunohistochemical phenotype on therapy response remain to be investigated.